PLoS Genetics (Feb 2017)

GWAS for serum galactose-deficient IgA1 implicates critical genes of the O-glycosylation pathway.

  • Krzysztof Kiryluk,
  • Yifu Li,
  • Zina Moldoveanu,
  • Hitoshi Suzuki,
  • Colin Reily,
  • Ping Hou,
  • Jingyuan Xie,
  • Nikol Mladkova,
  • Sindhuri Prakash,
  • Clara Fischman,
  • Samantha Shapiro,
  • Robert A LeDesma,
  • Drew Bradbury,
  • Iuliana Ionita-Laza,
  • Frank Eitner,
  • Thomas Rauen,
  • Nicolas Maillard,
  • Francois Berthoux,
  • Jürgen Floege,
  • Nan Chen,
  • Hong Zhang,
  • Francesco Scolari,
  • Robert J Wyatt,
  • Bruce A Julian,
  • Ali G Gharavi,
  • Jan Novak

DOI
https://doi.org/10.1371/journal.pgen.1006609
Journal volume & issue
Vol. 13, no. 2
p. e1006609

Abstract

Read online

Aberrant O-glycosylation of serum immunoglobulin A1 (IgA1) represents a heritable pathogenic defect in IgA nephropathy, the most common form of glomerulonephritis worldwide, but specific genetic factors involved in its determination are not known. We performed a quantitative GWAS for serum levels of galactose-deficient IgA1 (Gd-IgA1) in 2,633 subjects of European and East Asian ancestry and discovered two genome-wide significant loci, in C1GALT1 (rs13226913, P = 3.2 x 10-11) and C1GALT1C1 (rs5910940, P = 2.7 x 10-8). These genes encode molecular partners essential for enzymatic O-glycosylation of IgA1. We demonstrated that these two loci explain approximately 7% of variability in circulating Gd-IgA1 in Europeans, but only 2% in East Asians. Notably, the Gd-IgA1-increasing allele of rs13226913 is common in Europeans, but rare in East Asians. Moreover, rs13226913 represents a strong cis-eQTL for C1GALT1 that encodes the key enzyme responsible for the transfer of galactose to O-linked glycans on IgA1. By in vitro siRNA knock-down studies, we confirmed that mRNA levels of both C1GALT1 and C1GALT1C1 determine the rate of secretion of Gd-IgA1 in IgA1-producing cells. Our findings provide novel insights into the genetic regulation of O-glycosylation and are relevant not only to IgA nephropathy, but also to other complex traits associated with O-glycosylation defects, including inflammatory bowel disease, hematologic disease, and cancer.